Han-Fei Lin joined Lotus’s Board of Directors on June 27th, 2016.
Mr. Lin is currently the Chairman of Easywell Biomedicals, Inc. He has been a Partner and the Chief Strategy Officer with the CID Group since 2004. His earlier experience included serving as CFO for one of the largest fabless IC-design companies, MStar. During his tenure with MStar, he led MStar IPO (ranked as one of the largest IPOs in Taiwan Stock Exchange history). He later completed its merger with Mediatek to create the leading semiconductor company in the Greater China region.
Han-Fei started his career on Wall Street across various functions, including Corporate Strategy Planning for Citigroup’s Chairman office and Vice President, Mergers and Acquisitions for Citigroup/Salomon Smith Barney. In addition, Han-Fei had funded early-stage biotech ventures and served as CEO of Asia Bioinnovations. Before this, Han-Fei served as Director of Investments for Foxconn’s US ventures.